Dr. Bertrand M. Anz III, MD

Dr. Anz practices at Tennessee Oncology in Chattanooga, Tennessee.

Dr. Anz's NPI, 1205996014, was assigned on December 11, 2006. Dr. Anz graduated from Frederick P. Whiddon College of Medicine in 2004. Dr. Anz holds Tennessee license MD0000046093.

Dr. Anz's primary practice is Tennessee Oncology, at 605 Glenwood Dr, Chattanooga, TN 37404 in Hamilton County. The practice phone is (615) 329-0570.

Dr. Anz's primary practice is Tennessee Oncology in Chattanooga, Tennessee. Dr. Anz is also affiliated with Erlanger Baroness Hospital. The medical group on file is Tennessee Oncology. Dmand AI also links Dr. Anz to 4 more hospitals, 2 group practices and clinics, 2 home health agencies and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Anz practices, 9 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Anz's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Anz is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Anz's licenses on file in 4 states: Tennessee, Georgia, Alabama and North Carolina.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), fluid and electrolyte imbalances, lung cancer and lymphoma among the conditions Dr. Anz treats.

CMS data shows 209,595 Medicare services from Dr. Anz across 90 procedure codes in 2024, for 1,041 Medicare patients. Medicare paid $3,214,218 for them.

CMS counts 1,041 Medicare patients who saw Dr. Anz in 2024. The largest group is 65 to 74, with 429 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 10% are also on Medicaid. Their average risk score is 2.18, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Anz's median patient age at 69, with 56% women.

In 2024, Dr. Anz wrote 3,134 Medicare Part D claims for 462 patients. 67% of them were for generic drugs. CMS names the drug for 2,665 of them, across 67 drugs with 11 or more claims each, at $9,850,582 in total drug cost. In 2023, CMS named 2,287 claims across 61 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Anz for performance year 2024, reported as part of a group. Dr. Anz accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 6 papers to Dr. Anz, published from 2018 to 2022. The most frequent topics are Antibodies, Monoclonal, Humanized, Adenine and Chlorambucil. Dr. Anz has published most often in Haematologica. Dr. Anz's most frequent co-authors are Ian Winchester Flinn, MD, Ayed O. Ayed, MD and Paul Michael Barr, MD.

Dmand AI links Dr. Anz to 4 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelomonocytic, Chronic and Myelodysplastic Syndromes. Open Payments lists research payments to Dr. Anz that name 1 trial.

CMS Open Payments shows 216 general payments to Dr. Anz from 40 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 52% of the total. Celgene Corporation paid the most, $4,124. It also lists 8 research payments totaling $14,738 from 2017 to 2025, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Anz, most recently CMS Stage 1 EHR in 2012.

Dr. Anz graduated from Frederick P. Whiddon College of Medicine in 2004.

Dr. Anz is in network with 17 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Cigna. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.